Anti-Myeloproliferative leukemia virus oncogene Antibody, Non-Fucosylated (BioBet-1239ZP) (CAT#: BioBet-1239ZP) Datasheet

MPL

MPL proto-oncogene, thrombopoietin receptor

In 1990 an oncogene, v-mpl, was identified from the murine myeloproliferative leukemia virus that was capable of immortalizing bone marrow hematopoietic cells from different lineages. In 1992 the human homologue, named, c-mpl, was cloned. Sequence data revealed that c-mpl encoded a protein that was homologous with members of the hematopoietic receptor superfamily. Presence of anti-sense oligodeoxynucleotides of c-mpl inhibited megakaryocyte colony formation. The ligand for c-mpl, thrombopoietin, was cloned in 1994. Thrombopoietin was shown to be the major regulator of megakaryocytopoiesis and platelet formation. The protein encoded by the c-mpl gene, CD110, is a 635 amino acid transmembrane domain, with two extracellular cytokine receptor domains and two intracellular cytokine receptor box motifs. TPO-R deficient mice were severely thrombocytopenic, emphasizing the important role of CD110 and thrombopoietin in megakaryocyte and platelet formation. Upon binding of thrombopoietin CD110 is dimerized and the JAK family of non-receptor tyrosine kinases, as well as the STAT family, the MAPK family, the adaptor protein Shc and the receptors themselves become tyrosine phosphorylated.

MPL; MPL proto-oncogene, thrombopoietin receptor; MPLV; TPOR; C-MPL; CD110; THCYT2; thrombopoietin receptor; TPO-R; proto-oncogene c-Mpl; myeloproliferative leukemia protein; myeloproliferative leukemia virus oncogene

Golgi apparatus, Plasma membrane

Diseases associated with MPL include Myelofibrosis and Amegakaryocytic Thrombocytopenia, Congenital.

Its related pathways are PEDF Induced Signaling and Hematopoietic Stem Cells and Lineage-specific Markers.

Receptor for thrombopoietin that acts as a primary regulator of megakaryopoiesis and platelet production. May represent a regulatory molecule specific for TPO-R-dependent immune responses.

Controls and Markers antibody; Tag Internal Control antibody; Fluorescent-Tags antibody

1.Ubiquitination at Lys-553 and Lys-573 targets MPL for degradation by both the lysosomal and proteasomal pathways. The E3 ubiquitin-protein ligase CBL significantly contributes to this ubiquitination 2.Modification sites at PhosphoSitePlus 3.Glycosylation at Asn117, Asn178, Asn298, and Asn358 4.Ubiquitination at Lys553 and Lys573

Protein Based Therapies
Monoclonal antibody (mAb)

IgG

BioBet-1239ZP

Humanized

Human

The antibody which specifically bind to human c-MPL are useful for treating certain diseases such as cancer (such as leukemias) and the like.

Cancer

Cancer